Huaxing New Economic Fund Investment Project Yaomingkangde Appears Successfully on Shanghai Stock Exchange

On May 8, 2018, Wuxi Yaoming Kangde New Drug Development Co., Ltd was formally listed on the Shanghai Stock Exchange. Yaoming Kangde is the invested company of Huaxing New Economic Fund. Huaxing Capital is very fortunate to be able to accompany the growth of the company and to jointly witness the achievements it had made today

.

     Yaoming kangde's issue price is RMB 21.60 per share and the number of issued shares is 10,419.86 million. The raised funds will be used for the expansion project of Suzhou Drug Safety Evaluation Center, the expansion project of Tianjin Chemical R&D Labs, the headquarters of WuXi PharmaTech's headquarters, and analysis and diagnosis Service R&D center project and supplement liquidity.

  Through this A-share listing, Yaomingkangde will leverage the capital market to further enhance its technology and capability platform, reduce the cost of research and development of new drugs, increase research and development efficiency, and allow more innovative drugs to enter the market as soon as possible to benefit patients.

In the second half of 2015, the Yaomingkangde Group was privatized from the New York Stock Exchange. The Huaxing New Economic Fund has invested in the Group as a whole. After Yaomingkangde Group delisted from the stock market, and Huaxing New Economic Fund held the shares of this A-share listed WuXi MingKang New Drug, and it also holds the stock of Yaoming Bio shares that has been listed on the Hong Kong Stock Exchange on June 13, 2017.